<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33735585</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.</ArticleTitle>
        <Pagination>
          <StartPage>1879578</StartPage>
          <MedlinePgn>1879578</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1879578</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1879578</ELocationID>
        <Abstract>
          <AbstractText>In 2010, a 10-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) was introduced in the Brazilian national immunization program; the 3 + 1 dose schedule was replaced by a 2 + 1 dose schedule in 2016. This systematic review presents the latest published evidence (2015-2020) on the impact after 10-year use of PHiD-CV in Brazil from a total of 29 publications. Overall, the PHiD-CV program had a positive impact on the morbidity and mortality associated with invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) in children &lt;5 years-old. A reduction in the vaccine-type invasive disease was observed in all-ages; suggesting indirect protection unvaccinated older children and adults. The occurrence of non-vaccine type disease was evidenced in some studies. Higher vaccination coverage is required at national and state level for sustained population impact. Given the change in the vaccination schedule and the dynamics of pneumococcal disease epidemiology, continuous surveillance is warranted.GSK Study identifier: HO-18-19438.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guzman-Holst</LastName>
            <ForeName>Adriana</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-6753-2541</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Panama City, Panama.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Barros</LastName>
            <ForeName>Eliana</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>GSK, Rio de Janeiro, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rubio</LastName>
            <ForeName>Pilar</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>GSK, Rio de Janeiro, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeAntonio</LastName>
            <ForeName>Rodrigo</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-2586-4115</Identifier>
            <AffiliationInfo>
              <Affiliation>Centro de Vacunación Internacional S.A. CEVAXIN, Panama City, Panama.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cintra</LastName>
            <ForeName>Otavio</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abreu</LastName>
            <ForeName>Ariane</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Nacional de Cardiologia, Rio de Janeiro, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010033" MajorTopicYN="Y">Otitis Media</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Brazil</Keyword>
        <Keyword MajorTopicYN="Y">PCV</Keyword>
        <Keyword MajorTopicYN="Y">Pneumonia</Keyword>
        <Keyword MajorTopicYN="Y">Streptococcus pneumoniae</Keyword>
        <Keyword MajorTopicYN="Y">acute otitis media</Keyword>
        <Keyword MajorTopicYN="Y">impact</Keyword>
        <Keyword MajorTopicYN="Y">invasive pneumococcal disease</Keyword>
        <Keyword MajorTopicYN="Y">nasopharyngeal carriage</Keyword>
        <Keyword MajorTopicYN="Y">vaccination</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33735585</ArticleId>
        <ArticleId IdType="pmc">PMC8920160</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1879578</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>World Health Organization . Weekly epidemiological record, Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – february 2019. 2019. [accessed 21
Apr 2019]. https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf?ua=1</Citation>
        </Reference>
        <Reference>
          <Citation>de Moraes JC, Barata R, Ribeiro MC, de Castro PC.. 
Vaccination coverage in the first year of life in 4 cities of the state of Sao Paulo, Brazil. Rev Panam. Salud Publica. 2000;8:332–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11190970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreira M, Cintra O, Harriague J, Hausdorff WP, Hoet B. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program. Vaccine. 2016;34(25):2766–78. doi:10.1016/j.vaccine.2016.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.04.006</ArticleId>
            <ArticleId IdType="pubmed">27113162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ministério da Saude Brasil . Nota informativa N◦149. Informa as mudanc¸ as noCalendario Nacional de Vacinac¸ ão para o ano de 2016; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Russell F, Sanderson C, Temple B, Mulholland K. 
Global review of the distribution of pneumococcal disease by age and region; 2011. [Accessed 21
Jul 2019] https://www.who.int/immunization/sage/6_Russel_review_age_specific_epidemiology_PCV_schedules_session_nov11.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Whitney CG, Goldblatt D, O’Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J. 2014;33(Suppl 2):S172–181. doi:10.1097/inf.0000000000000076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000000076</ArticleId>
            <ArticleId IdType="pmc">PMC3940379</ArticleId>
            <ArticleId IdType="pubmed">24336059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine. 2017;35(22):2882–91. doi:10.1016/j.vaccine.2017.04.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.04.032</ArticleId>
            <ArticleId IdType="pubmed">28449971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brazilian Ministry of Health . IMUNIZAÇÕES - COBERTURA – BRASIL; 2018. [accessed 07
Jun 2018]. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?pni/cnv/cpnibr.def</Citation>
        </Reference>
        <Reference>
          <Citation>Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infect Dis. 2012;12:207. doi:10.1186/1471-2334-12-207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2334-12-207</ArticleId>
            <ArticleId IdType="pmc">PMC3462147</ArticleId>
            <ArticleId IdType="pubmed">22954038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId>
            <ArticleId IdType="pmc">PMC2707599</ArticleId>
            <ArticleId IdType="pubmed">19621072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, The MD. PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1000100</ArticleId>
            <ArticleId IdType="pmc">PMC2707010</ArticleId>
            <ArticleId IdType="pubmed">19621070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi:10.1371/journal.pmed.0040297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.0040297</ArticleId>
            <ArticleId IdType="pmc">PMC2020496</ArticleId>
            <ArticleId IdType="pubmed">17941715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666–76. doi:10.1093/ije/dym018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ije/dym018</ArticleId>
            <ArticleId IdType="pubmed">17470488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fowkes FG, Fulton PM. Critical appraisal of published research: introductory guidelines. BMJ (Clinical Research Ed.). 1991;302:1136–40. doi:10.1136/bmj.302.6785.1136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.302.6785.1136</ArticleId>
            <ArticleId IdType="pmc">PMC1669795</ArticleId>
            <ArticleId IdType="pubmed">2043787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, Phillips B, Lelgemann M, Lethaby A, Bousquet J, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669–77. doi:10.1111/j.1398-9995.2009.01973.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2009.01973.x</ArticleId>
            <ArticleId IdType="pubmed">19210357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nunes SEA
ESTIMATIVA DOS CUSTOS DA DOENÇA PNEUMOCÓCICA E ESTUDO DE CUSTO-EFETIVIDADE DA INTRODUÇÃO UNIVERSAL DA VACINA ANTI-PNEUMOCÓCICA 10 VALENTE NO BRASIL; 2014. [Accessed 21
Jul 2019]. https://repositorio.bc.ufg.br/tede/bitstream/tede/7547/5/Tese%20-%20Sheila%20Elke%20Ara%C3%BAjo%20Nunes%20-%202014.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Andrade AL, Afonso ET, Minamisava R, Bierrenbach AL, Cristo EB, Morais-Neto OL, Policena GM, Domingues C, Toscano CM. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis. PloS One. 2017;12:e0184204. doi:10.1371/journal.pone.0184204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0184204</ArticleId>
            <ArticleId IdType="pmc">PMC5589174</ArticleId>
            <ArticleId IdType="pubmed">28880953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azevedo J, Dos Anjos ES, Cordeiro SM, Dos Santos MS, Escobar EC, Lobo PR, Carvalho MD, Reis MG, Reis JN, Campos LC. Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil. J Med Microbiol. 2016;65(10):1164–70. doi:10.1099/jmm.0.000346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jmm.0.000346</ArticleId>
            <ArticleId IdType="pubmed">27599851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berezin EN, Jarovsky D, Cardoso MRA, Mantese OC. Invasive pneumococcal disease among hospitalized children in Brazil before and after the introduction of a pneumococcal conjugate vaccine. Vaccine. 2020;38(7):1740–45. doi:10.1016/j.vaccine.2019.12.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.12.038</ArticleId>
            <ArticleId IdType="pubmed">31874778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandileone MC, Almeida SCG, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–66. doi:10.1016/j.vaccine.2018.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.04.010</ArticleId>
            <ArticleId IdType="pubmed">29650385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandileone MC, Zanella RC, Almeida SCG, Brandao AP, Ribeiro AF, Carvalhanas TMP, Sato H, Andrade AL, Verani JR. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo, Brazil. Vaccine. 2016;34(46):5604–11. doi:10.1016/j.vaccine.2016.09.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.09.027</ArticleId>
            <ArticleId IdType="pubmed">27692770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandileone MC, Zanella RC, Almeida SCG, Cassiolato AP, Lemos APS, Salgado MM, Higa FT, Minamisava R, Andrade AL. Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil. Vaccine. 2019;37(36):5357–63. doi:10.1016/j.vaccine.2019.07.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.07.043</ArticleId>
            <ArticleId IdType="pubmed">31351796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassiolato AP, Almeida SCG, Andrade AL, Minamisava R, Brandileone MCC. Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS One. 2018;13(11):e0208211. doi:10.1371/journal.pone.0208211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0208211</ArticleId>
            <ArticleId IdType="pmc">PMC6264150</ArticleId>
            <ArticleId IdType="pubmed">30496296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupek E, Vieira IL. [Impact of PCV10 pneumococcal vaccine on mortality from pneumonia in children less than one year of age in Santa Catarina State, Brazil]. Cad Saude Publica. 2016;32(3):e00131414. doi:10.1590/0102-311x00131414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/0102-311x00131414</ArticleId>
            <ArticleId IdType="pubmed">27049314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurum E, Warren JL, Schuck-Paim C, Lustig R, Lewnard JA, Fuentes R, Bruhn CAW, Taylor RJ, Simonsen L, Weinberger DM. Bayesian model averaging with change points to assess the impact of vaccination and public health interventions. Epidemiology (Cambridge, Mass.). 2017;28(6):889–97. doi:10.1097/ede.0000000000000719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ede.0000000000000719</ArticleId>
            <ArticleId IdType="pmc">PMC5617796</ArticleId>
            <ArticleId IdType="pubmed">28767518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite CR, Azevedo J, Galvao VS, Moreno-Carvalho O, Reis JN, Nascimento-Carvalho C. Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil. Brazil J Infect Dis off Publ Brazilian Soc Infect Dis. 2016;20(1):56–60. doi:10.1016/j.bjid.2015.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bjid.2015.10.005</ArticleId>
            <ArticleId IdType="pubmed">26706019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros MI, Negrini BV, Silva JM, Almeida SC, Leopoldo ML, Guerra S, Andrade D. Clinical and microbiological implications of invasive pneumococcal disease in hospitalized patients (1998-2013). Brazil J Infect Dis off Publ Brazilian Soc Infect Dis. 2016;20(3):242–49. doi:10.1016/j.bjid.2016.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bjid.2016.01.011</ArticleId>
            <ArticleId IdType="pubmed">27094236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros MIC, Almeida SCG, Guerra M, da Silva P, Carneiro AMM, de Andrade D. Distribution of Streptococcus pneumoniae serotypes in the northeast macro-region of Sao Paulo state/Brazil after the introduction of conjugate vaccine. BMC Infect Dis. 2017;17(1):590. doi:10.1186/s12879-017-2696-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-017-2696-y</ArticleId>
            <ArticleId IdType="pmc">PMC5574098</ArticleId>
            <ArticleId IdType="pubmed">28841854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neves FPG, Cardoso NT, Snyder RE, Marlow MA, Cardoso CAA, Teixeira LM, Riley LW. Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: the emergence of multidrug resistant serotype 6C. Vaccine. 2017;35(21):2794–800. doi:10.1016/j.vaccine.2017.04.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.04.019</ArticleId>
            <ArticleId IdType="pubmed">28431817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira JR, Bouzas ML, Cardoso MR, Barral A, Nascimento-Carvalho C. Frequency of complications and the effects of pneumococcal vaccination in young children with acute respiratory tract infection. Vaccine. 2016;34(23):2556–61. doi:10.1016/j.vaccine.2016.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.04.015</ArticleId>
            <ArticleId IdType="pubmed">27102819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sartori AL, Minamisava R, Bierrenbach AL, Toscano CM, Afonso ET, Morais-Neto OL, Antunes JLF, Cristo EB, Andrade AL. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PloS One. 2017;12(6):e0179222. doi:10.1371/journal.pone.0179222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0179222</ArticleId>
            <ArticleId IdType="pmc">PMC5464612</ArticleId>
            <ArticleId IdType="pubmed">28594913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuck-Paim C, Taylor RJ, Alonso WJ, Weinberger DM, Simonsen L. Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study. Lancet Global Health. 2019;7(2):e249–e256. doi:10.1016/S2214-109X(18)30455-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2214-109X(18)30455-8</ArticleId>
            <ArticleId IdType="pmc">PMC6344339</ArticleId>
            <ArticleId IdType="pubmed">30683242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sgambatti S, Minamisava R, Afonso ET, Toscano CM, Bierrenbach AL, Andrade AL. Appropriateness of administrative data for vaccine impact evaluation: the case of pneumonia hospitalizations and pneumococcal vaccine in Brazil. Epidemiol Infect. 2015;143(2):334–42. doi:10.1017/s0950268814000922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/s0950268814000922</ArticleId>
            <ArticleId IdType="pubmed">24759601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva S, Mello L, Silva A, Nunes AA. Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children. Revista paulista de pediatria: orgao oficial da Sociedade de Pediatria de Sao Paulo. 2016;34:418–424. doi:10.1016/j.rpped.2016.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rpped.2016.02.003</ArticleId>
            <ArticleId IdType="pmc">PMC5176061</ArticleId>
            <ArticleId IdType="pubmed">27108092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieira ILV, Kupek E. The impact of pneumococcal vaccine in reducing pneumonia hospitalizations in children under 5 years old, in Santa Catarina, Brazil, 2006 a 2014. Epidemiol Serv Saude. 2018;27(4):e2017378. http://europepmc.org/abstract/MED/30517348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30517348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade AL, Minamisava EB, Policena G, Cristo EB, Morais-Neto OL, Cmas D. 
Effect of 10-valent pneumococcal conjugate vaccine on meningitis and invasive disease after 3 years of routine immunization in Brazil. 33rd Annual European Society for Paediatric Infectious Diseases Meeting (ESPID-33); 2015; Leipzig, Germany.</Citation>
        </Reference>
        <Reference>
          <Citation>Costa CG, Ferreira MS, Vasconcelos LVS, Vasconcelos, Lino R, Marani MLC, Siqueira SCDF. Uso De Pcv-10 E Hospitalizacoes Por Pneumonia Em Criancas De 1 A 4 Anos No Estado Do Maranhao De 2008 A 2013: Um Estudo Antes E Depois. 37th Congresso Brasileiro de Pediatria; 2015; Rio de Janeiro, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>De Oliveira M, De Araujo MHMA, De Almeida JP, Da Costa AJA, De Almeida SP. Analise Comparativa Regional E Estadual Da Taxa De Mortalidade Infantil Por Pneumonia Nos Anos De 2006 E 2016 No Brasil. 38th Congresso Brasileiro de Pediatria; 2017; Rio de Janeiro, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>de Paulo SB, Aguiar DAP, Baroni AR, de Souza DI, Bahzuni SF, Couto PMM, Amaral SAC, Parente A. Antipneumococcal vaccine status of children hospitalized for community acquired pneumonia (CAP) at a Brazilian Pediatric Hospital. 16th International Congress of Pediatric Pulmonology (CIPP XVI); 2017; Lisbon, Portugal.</Citation>
        </Reference>
        <Reference>
          <Citation>Jarovsky D, Almeid S, Mantese OD, Berezin N. Evaluation of pneumococcal conjugate vaccination impact in seroprevalence of streptococcus pneumoniae in Brazilian children at different age groups. 34rd Annual European Society for Paediatric Infectious Diseases Meeting (ESPID-34); 2016; Brighton, UK.</Citation>
        </Reference>
        <Reference>
          <Citation>Jarovsky D, De Assis ACD, Monaco DF, De Almeida RJS, Almeda F, Berezin EN. 
Estudo De Vigilancia Em Meningite Pneumococica Em Um Periodo De 16 Anos: Avaliacao Do Impacto Da Vacina Conjugada 10-Valente Nos Sorotipos E Na Resistencia Antimicrobiana Em Diversas Faixas Etarias. 19th Congresso Brasileiro de Infectologia Pediatrica; 2016; Fortaleza, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>Jarovsky D, Naaman EB, Josa R, Almeida SD. 
Invasive pneumococcal disease in a population with underlying comorbidities. IDWeek; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Marani M, Ferreira MS, Silva LM, De Souza CC, De Paula J. Uso De Pcv 10 E Hospitalizacoes Por Pneumonia Em Criancas De 1 A 4 Anos No Estado Do Tocantins De 2008 A 2013: Um Estudo Antes E Depois. 37th Congresso Brasileiro de Pediatria; 2015; Rio de Janeiro, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>Oliveira W, Santos LTR, Gomes ARS. 
Mortalidade Infantil Por Pneumonias: Analise Comparativa De Dois Quinquenios. 38th Congresso Brasileiro de Pediatria; 2017; Rio de Janeiro, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>Yoshioka CRM, Gilio AE, Brandileone MCDC, Guida SM, Balabakis A, Grassi SC. 
Caracteristicas Epidemiologicas Das Criancas Com Doencas Invasivas Pneumococicas Nos Periodos Pre E Pos Vacina Pneumococica 10-Valente Num Hospital Geral Na Comunidade De Butanta-Sao Paulo. 19th Congresso Brasileiro de Infectologia Pediatrica; 2016; Rio de Janeiro, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. doi:10.1016/j.jclinepi.2010.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.026</ArticleId>
            <ArticleId IdType="pubmed">21195583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–40. doi:10.1016/j.vaccine.2018.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.03.001</ArticleId>
            <ArticleId IdType="pubmed">29526371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Kilpi TM, Jokinen J. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PloS One. 2017;12(3):e0172690. doi:10.1371/journal.pone.0172690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0172690</ArticleId>
            <ArticleId IdType="pmc">PMC5332024</ArticleId>
            <ArticleId IdType="pubmed">28249015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nhantumbo AA, Weldegebriel G, Katsande R, de Gouveia L, Come CE, Cuco AZ, Cantarelli VV, Dias C, Caierao J, Mathiu JM, et al. Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013-2015. PloS One. 2017;12(6):e0177746. doi:10.1371/journal.pone.0177746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0177746</ArticleId>
            <ArticleId IdType="pmc">PMC5467806</ArticleId>
            <ArticleId IdType="pubmed">28604773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agudelo CI, DeAntonio R, Castañeda E. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010-2015: A systematic review and a time series analysis. Vaccine. 2018;36(32):4861–74. doi:10.1016/j.vaccine.2018.06.068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.06.068</ArticleId>
            <ArticleId IdType="pubmed">30005949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. doi:10.1371/journal.pmed.1001517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1001517</ArticleId>
            <ArticleId IdType="pmc">PMC3782411</ArticleId>
            <ArticleId IdType="pubmed">24086113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93. doi:10.1080/14760584.2018.1413354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2018.1413354</ArticleId>
            <ArticleId IdType="pubmed">29241390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. The Lancet Infectious Diseases. 2019;19(6):e213–e220. doi:10.1016/s1473-3099(18)30660-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(18)30660-1</ArticleId>
            <ArticleId IdType="pubmed">30709666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. The Lancet Respiratory Medicine. 2017;5(8):648–56. doi:10.1016/s2213-2600(17)30110-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s2213-2600(17)30110-8</ArticleId>
            <ArticleId IdType="pubmed">28359798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Hanage WP. Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74. doi:10.1080/21645515.2015.1118593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2015.1118593</ArticleId>
            <ArticleId IdType="pmc">PMC5049718</ArticleId>
            <ArticleId IdType="pubmed">26905681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–28. doi:10.1586/14760584.2015.965160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2015.965160</ArticleId>
            <ArticleId IdType="pubmed">25266168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargos P, Nascimento-Carvalho CM, Teixeira R, Franca E. Lower respiratory infections mortality among Brazilians under-five before and after national pneumococcal conjugate vaccine implementation. Vaccine. 2020;38(11):2559–65. doi:10.1016/j.vaccine.2020.01.084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2020.01.084</ArticleId>
            <ArticleId IdType="pubmed">32033849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–55. doi:10.1586/erv.12.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/erv.12.53</ArticleId>
            <ArticleId IdType="pubmed">22913260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francisco PM, Donalisio MR, Barros MB, Cesar CL, Carandina L, Goldbaum M. Factors associated with vaccination against influenza in the elderly. Rev Panam. Salud Publica. 2006;19:259–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16723067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–64. doi:10.1016/j.vaccine.2015.04.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.04.036</ArticleId>
            <ArticleId IdType="pubmed">25896383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita DM, Salvador FS, Nali L, Luna EJA. Decreasing vaccine coverage rates lead to increased vulnerability to the importation of vaccine-preventable diseases in Brazil. J Travel Med. 2018;25(1). doi:10.1093/jtm/tay100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jtm/tay100</ArticleId>
            <ArticleId IdType="pubmed">30312442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato APS. What is the importance of vaccine hesitancy in the drop of vaccination coverage in Brazil?
Rev Saude Publica. 2018;52:96. doi:10.11606/s1518-8787.2018052001199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.11606/s1518-8787.2018052001199</ArticleId>
            <ArticleId IdType="pmc">PMC6284490</ArticleId>
            <ArticleId IdType="pubmed">30517523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sartori AL, Minamisava R, Afonso ET, Policena GM, Pessoni GC, Bierrenbach AL, Andrade AL. Timeliness and risk factors associated with delay for pneumococcal conjugate 10-valent routine immunization in Brazilian children. Vaccine. 2017;35(7):1030–36. doi:10.1016/j.vaccine.2017.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.01.012</ArticleId>
            <ArticleId IdType="pubmed">28108230</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
